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Imaging the Vulnerable Plaque
David Vancraeynest, MD, PHD, Agnes Pasquet, MD, PHD, Véronique Roelants, MD,
Bernhard L. Gerber, MD, PHD, Jean-Louis J. Vanoverschelde, MD, PHD
Brussels, Belgium
Cardiovascular diseases are still the primary causes of mortality in the United States and in Western Europe.
Arterial thrombosis is triggered by a ruptured atherosclerotic plaque and precipitates an acute vascular event,
which is responsible for the high mortality rate. These rupture-prone plaques are called “vulnerable plaques.”
During the past decades, much effort has been put toward accurately detecting the presence of vulnerable
plaques with different imaging techniques. In this review, we provide an overview of the currently available inva-
sive and noninvasive imaging modalities used to detect vulnerable plaques. We will discuss the upcoming chal-
lenges in translating these techniques into clinical practice and in assigning them their exact place in the
decision-making process. (J Am Coll Cardiol 2011;57:1961–79) © 2011 by the American College of Cardiology
Foundation
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.02.018Each year in Europe and in the United States, atheroscle-
rotic diseases, including acute coronary syndromes (ACS)
and stroke, are responsible for nearly one-half of all deaths
and are among the leading causes of disability (1,2). Al-
though atherosclerosis alone is a relatively benign disease, it
is frequently complicated by acute thrombosis, usually trig-
gered by the rupture or erosion of an atherosclerotic plaque,
which in turn precipitates the acute ischemic events. Until
now, identification of patients at high risk for acute vascular
events has mainly relied on the estimation of their 10-year
probability to present with or to die from an acute coronary
or vascular problem with either the Framingham risk
equation (3) or the Systematic Coronary Risk Evaluation
system (4). Unfortunately, although these scores correctly
estimate the cardiovascular risk of men of middle-age, they
usually greatly underestimate that of younger patients (5,6).
oninvasive tests such as stress single-photon emission
omputed tomography (SPECT) or stress echocardiography
re frequently used to refine cardiovascular risk assessment
n high-risk individuals. These tests provide information on
he hemodynamic significance of potential coronary artery
tenoses. Accordingly, they only allow for the identification
f the most severely obstructive plaques (i.e., those that limit
oronary flow reserve). Because most vascular events are
aused by the rupture or erosion of nonhemodynamically
ignificant plaques, which by far outnumber flow-limiting
esions (probably by a factor of 10) (7), the predictive value
f noninvasive stress testing in predicting acute vascular
vents is particularly poor. More recently, coronary calcium
From the Pôle de Recherche Cardiovasculaire, Institut de Recherche Expérimentale
et Cliniques, Université Catholique de Louvain, Brussels, Belgium. The authors have
reported that they have no relationships to disclose.
Manuscript received February 9, 2011, accepted February 15, 2011.scoring (8), with computed tomography, and various in-
flammatory biomarkers (9) have been proposed to help risk
stratify high-risk patients. Although these tests do improve
our ability to identify patients at risk, their predictive value
remains too low to be used in daily clinical practice.
During the past decade, development of new tools to
identify “vulnerable atherosclerotic plaques” (i.e., those
likely to cause an acute vascular event) has focused consid-
erable attention. It is the aim of the present review to
summarize the current state of knowledge in this fast-
evolving field and to discuss some of the challenges in
translating this knowledge into clinical practice. This review
gives a short description of the techniques, their validation,
their possible clinical usefulness, and their limitations.
Pathogenesis of Vulnerable Atherosclerotic Plaques:
Structural, Cellular, and Functional Features
Associated With Plaque “Vulnerability”
Atherosclerotic lesions are focal thickening of the intima of
arteries of large and medium size. Lipids, inflammatory and
smooth muscle cells, as well as connective tissue are system-
atically found in these lesions. In patients with hypercho-
lesterolemia, low-density lipoprotein (LDL) particles in
excess infiltrate the artery and are retained in the intima,
particularly at sites of hemodynamic strain (10). Local
oxidative and enzymatic modifications of LDL particles
lead to the release of inflammatory lipids that induce
endothelial cells to express leukocyte adhesion molecules
such as vascular cell adhesion molecule (VCAM)-1,
E-selectin, and P-selectin, which in turn facilitates the
recruitment of white blood cells, including T-lymphocytes
and monocytes (11,12). Monocytes recruited through the
activated endothelium differentiate into macrophages. The
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up by the scavenger receptors of
these macrophages, which evolve
into foam cells. Several endoge-
nous molecules can ligate toll-like
receptors on these cells, inducing
their activation and leading to the
release of inflammatory cytokines,
chemokines, oxygen and nitrogen
radicals, and other inflammatory
molecules (12,13). During the
progression of atherosclerosis, en-
dothelial cells, macrophages, and
smooth muscle cells die from ap-
optosis or necrosis (14). Disinte-
gration of foam cells, loss of
smooth muscle cells, and produc-
tion of matrix metalloproteinases
by activated leukocytes have detri-
mental consequences—leading to
the formation of destabilizing lipid-
rich cores and fragile and rupture-
prone fibrous caps (11,15). Angio-
genesis is also frequent in advanced
atherosclerosis and is probably a
marker of ongoing disease activity
and might thus characterize high-
risk plaques. There is evidence that
hypoxia plays an important role in
triggering microvessel proliferation
in the inner layers of the vessel
wall, to compensate for the limited
diffusion of oxygen in large atherosclerotic plaques. The new
microvessels originate from adventitial vasa vasorum. They
are immature, fragile, and leaky and express cellular adhe-
sion molecules, resulting in local extravasation of plasma
proteins, erythrocytes (bleeding), and inflammatory cells
(16–18).
The morphological traits typically associated with
rupture-prone plaques (11,19–21) are found in lesions
usually referred to as thin-cap fibroatheroma (TCFA) and
are shown in Figure 1. They include a large eccentric
necrotic core, occupying approximately one-quarter of the
plaque area (22), a thin fibrous cap, usually 65 m (23),
heavily infiltrated with macrophages and inflammatory cells
(24), spotty calcifications, and vasa vasorum proliferation.
Although two-thirds of acute events result from the rupture
of a TCFA, the remaining events are caused by erosion of
the intimal surface, with subsequent local thrombus forma-
tion (19). Eroded lesions usually exhibit less-severe luminal
narrowing, fewer calcifications, less-extensive intraplaque
neoangiogenesis, and less inflammation than ruptured
plaques. By contrast, they usually demonstrate more nega-
tive than positive remodeling. These characteristics make
Abbreviations
and Acronyms
ACS  acute coronary
syndrome(s)
FDG  18F-labeled
fluorodeoxyglucose
IB  integrated
backscatter
IVUS  intravascular
ultrasound
LDL  low-density
lipoprotein
MDCT  multidetector
computed tomography
MRI  magnetic resonance
imaging
NIRS  near-infrared
spectroscopy
OCT  optical coherence
tomography
RF  radiofrequency
RGD  arginine-glycine-
aspartic acid
SPECT  single-photon
emission computed
tomography
TCFA  thin-cap
fibroatheroma
VCAM  vascular cell
adhesion molecule
VH  virtual histologythem more difficult to detect than TCFAs.Intravascular Assessment of Plaque Vulnerability
Intravascular imaging aims at detecting vulnerable and
unstable atherosclerotic plaques in patients undergoing in-
vasive coronary angiography. Accordingly, it can only be
used in patients with a definite clinical indication for
invasive angiography. Because of their invasive nature,
intravascular imaging modalities are not suited to detect
patients with subclinical disease (i.e., those who are still
asymptomatic but are at high risk for future acute vascular
events).
Table 1 provides the diagnostic criteria, histological
targets, validation, clinical status, and limitations of each
technique. Table 2 compares the technical characteristics of
the various invasive techniques and shows the assumption
that legitimates their use in the vulnerable plaque assessment.
Intravascular ultrasound. Intravascular ultrasound (IVUS)
is one of the first techniques used to assess the morpholog-
ical features of coronary plaques. Intravascular ultrasound
provides real-time cross-sectional tomographic images of
the examined vessel perpendicular to the long axis of the
catheter. The intensity of the backscatter signal is processed
into gray scale with a spatial resolution of 150 m at a frame
rate of 10 to 30 frames/s. Intravascular ultrasound provides
information on the anatomical characteristics of the plaque
and, to a lesser extent, on its composition (25,26). IVUS has
been shown to detect features associated with plaque vul-
nerability, such as an eccentric pattern; the presence of an
echolucent core, probably representing the lipid-rich core;
positive vessel wall remodeling, defined by the expansion of
the overall vessel without compromising the lumen (27);
presence of thrombi (28–30); plaque length (28); lumen
narrowing (29); and a spotty pattern of calcifications (31). In
patients with ACS, IVUS can also evidence multiple plaque
rupture sites (28,32), a feature that has been correlated with
systemic inflammation as measured by C-reactive protein
(33). Finally, when used serially in the same patient, IVUS
can demonstrate healing of plaque rupture under medical
treatment (34). Three major limitations of IVUS in identi-
fying a vulnerable plaque must be acknowledged. First,
because of its limited spatial resolution, IVUS does not
permit recognition of TCFAs, whose thickness is less than
the spatial resolution of the systems. Second, all but one
(27) of the published IVUS studies have dealt with the
ultrasonic aspects of ruptured plaques, which differ from
TCFA in several aspects and can hardly be used to identify
vulnerable plaques (Fig. 2). Finally, gray-scale IVUS cannot
accurately discriminate the elements of plaque composition,
because their relationship with the original acoustic signal is
distorted during the scan conversion process and can be
further altered by display controls such as brightness and
gain. These technical limitations will probably prevent
IVUS from ever becoming a clinically useful tool in the
assessment of plaque vulnerability.
IVUS-radiofrequency analysis. Analysis of the IVUS
acoustic signal before demodulation and scan conversion
-Pron
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limitations inherent to conventional gray-scale IVUS imag-
ing (35–37). The RF data are supposed to be more directly
related to the interaction of ultrasound with the tissue.
Different mathematical methods have been used for RF
data analysis, including autoregressive modeling (virtual
histology [VH]) (Volcano, Rancho Cordova, California),
fast Fourier transformation (integrated backscatter [IB]-
IVUS), and wavelet analysis (37).
In VH, the frequency spectrum is calculated with a
mathematical autoregression model for each line in a region
of interest and averaged over the width of the region. The
results of this analysis are displayed as a color-coded map
(Fig. 3) of plaque composition that is superimposed over
conventional gray-scale IVUS images (38). With VH,
plaque components are usually categorized into 4 tissue
types: fibrous, fibrofatty, calcified necrotic, and calcified
(36–38). The diagnostic accuracy of VH was validated
against histology, both in ex-vivo (36) and in vivo (39)
experiments. These studies have shown that the sensitivity,
specificity, and predictive accuracy of VH to detect necrotic
cores—the lesions more often associated with vulnerable
plaques—were 67.3%, 92.9%, and 88.3%, respectively (39).
Furthermore, TCFAs were found—with VH—to be more
prevalent in ACS than stable angina (40). Recently, the
PROSPECT (Providing Regional Observations to Study
Predictors of Events in the Coronary Tree) study has
provided important data about the accuracy of VH to
predict acute cardiac events. The presence of TCFAs
assessed by VH correlated well with subsequent risk of
major adverse cardiac events (hazard ratio: 3.35). Neverthe-
less, the authors acknowledged that, of 595 TCFAs iden-
Figure 1 Typical Morphological Traits Associated With Rupturetified by VH, only 26 were the culprit site of the subsequentevent at a median follow-up of 3.4 years, underlying the low
specificity of the method (41). Recent data raise questions
about the accuracy of VH to detect necrotic core (42).
Similar to gray-scale IVUS, VH has significant limitations
that might affect its ability to indentify vulnerable plaques.
For instance, VH is unable to distinguish thrombi from
other plaque components, which might explain some re-
cently conflicting data as to the size of necrotic cores in
“unstable” lesions (43). Virtual histology also has limited
spatial resolution, which precludes assessment of the most
prominent feature of TCFAs (i.e., fibrous cap thickness).
Combined use of RF data analysis and optical coherence
tomography (OCT), which has a much better spatial
resolution, might be useful in this regard (44,45).
Integrated backscatter IVUS is another RF technique
that has been used to characterize atherosclerotic plaques.
The IB values of the different tissue components can be used
to generate a color-coded IB-IVUS image, such as in VH.
Both ex vivo (46,47) and in vivo (48) studies have validated
the accuracy of this approach. Three-dimensional recon-
struction of IB values has been proposed as well, offering an
attractive possibility to monitor changes in tissue character-
istics over time (49).
Wavelet analysis is a mathematical model used to dis-
criminate a unique local wave within a complex signal.
Color-coded mapping of wavelet analysis allows for the
detection of lipid versus fibrous plaques, both in vitro and in
vivo, with a sensitivity between 81% and 83% and a
specificity between 82% and 85% (50).
Intravascular elastography: palpography. Elastography
measures the mechanical properties of tissue with a cross-
correlation analysis of RF-ultrasound signals recorded at
e Plaquesdifferent pressures. For intravascular purposes, elastography
1964 Vancraeynest et al. JACC Vol. 57, No. 20, 2011
Imaging the Vulnerable Plaque May 17, 2011:1961–79is called palpography. Palpography measures the local rate
of plaque deformation (strain) in response to the pulsating
force of blood pressure. A pressure differential of 4 mm Hg
is large enough to strain the vessel between 0% and 1%.
Invasive Techniques for Imaging the Vulnerable PlaqueTable 1 Invasive Techniques for Imaging the Vulnerable Plaque
Histological or
Physiological Targets
Histological Va
Correlation
Coefficient
IVUS Eccentric pattern NA
Outward remodeling NA
Lipid core (echolucent core) NA
Plaque area 0.87 (26)
Spotty calcifications NA
IVUS-RF analysis Plaque composition (fibrous,
fibro-fatty, calcified necrotic,
and calcified tissues)
No correlation (42)
Identification of TCFA NA
Palpography Plaque composition (fibrous,
fibro-fatty, fatty)
NA
Thin fibrous cap with
macrophage infiltration
0.82 (56)
OCT Plaque composition (Fibrous,
fibrocalcic, lipid-rich)
NA
Thin fibrous cap NA
Macrophages 0.84 (70)
Neoangiogenesis (OCT-Doppler) 0.475 (72)
Collagen content (polarization-
sensitive-OCT)
NA
NIRS Thin fibrous cap NA
Lipid core NA
Macrophages NA
IV-MRI Plaque composition (lipid,
fibrous, calcified tissues)
NA
Angioscopy Lipid core and thin fibrous cap
(yellow plaques)
NA
Thermography Macrophages 0.68 (90)
Shear-stress imaging Localized “high shear stress
pattern”
NA
See text for details.
Acc accuracy; ACS acute coronary syndromes; AHR  adjusted hazard risk; AUC area un
IVUS intravascular ultrasound; MACEmajor adverse cardiac event; NIRS near-infrared spect
value; RF  radiofrequency; Se  sensitivity; Sp  specificity; TCFA  thin-cap fibroatheroma; 
experience limited;   currently not used for clinical assessment or research tool.Palpography assesses 1 strain value/angle. The value is thenplotted as a color-coded contour at the lumen vessel
boundary to obtain a palpogram of the artery (51,52). When
local strain is normalized by intracoronary pressure, the local
modulus of elasticity can be calculated to assess vessel wall
n (Ref. #)
Prediction of
Clinical Outcomes
(Ref. #)
Clinical
Status LimitationsAccuracy
NA NA  Invasiveness, limited
spatial resolution,
limited temporal
resolution
NA NA
NA Echolucent zone is at
increased risk for
ACS (PPV: 71%,
NPV: 98%) (27)
NA Large eccentric plaque
area (67% vs. 57%)
is at increased risk
for ACS (27)
NA NA
0%–96% (36,39) Lipid area (70%)
predicts subsequent
ACS (PPV: 46%)
(48), TCFA correlates
with subsequent
MACE: HR: 3.35 (41)
 Invasiveness, limited
spatial resolution
NA 
0%, Sp: 80% (55) NA  Invasiveness, limited
spatial resolution,
cardiac motion
artefact
, Sp: 89% (56) Se:
, Sp: 92% (55)
NA 
: 71%–96%,
: 90%–98% (64)
NA  Invasiveness, limited
tissue penetration,
need for flushing or
for occlusion
balloon
NA NA 
%, Sp: 75% (70) NA 
89% NPV: 93% NA 
NA NA 
%, Sp: 93% (76) NA  Invasiveness, limited
tissue penetration,
cardiac motion
artefact
%, Sp: 93% (76);
UC: 0.86 (75)
NA 
%, Sp: 89% (76) NA 
: 73%–100%,
81%–89% (79,80)
NA  Invasiveness, need for
occlusion balloon
e: 94% (83) Yellow plaque predict
ACS: PPV: 28%,
NPV: 97% (85);
number of yellow
plaques predicts
ACS: AHR: 1.23 (86)
 Invasiveness, limited
tissue penetration,
spatial resolution,
need for flushing
and for occlusion
balloon
NA NA  Invasiveness, limited
tissue penetration,
limited spatial and
temporal resolution,
need for interruption
of blood flow
NA NA  Invasiveness, flow-
dependent, limited
spatial resolution
receiver-operating curve; HR hazard ratio; IV-MRI intravascular magnetic resonance imaging;
; NPV negative predictive value; OCT optical coherence tomography; PPV positive predictive
idely used in clinical routine;   must be validated in larger groups of patients;   clinicallidatio
Acc: 8
Se: 10
Se: 88%
92%
Se
Sp
Se: 70
PPV:
Se: 77
Se: 90
A
Se: 84
Se
Sp:
S
der the
roscopy
  wand plaque characteristics (51,52), fibrous plaques being
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against histopathology both ex vivo (53), on explanted
atherosclerotic human femoral and coronary arteries, and in
vivo, in a small group of patients scheduled for percutaneous
intervention (54) as well as in Yucatan pigs (55). In ex vivo
experiments, good correlations were found between the
presence of TCFAs or macrophage infiltration and high
regional strain values (Fig. 4) (56). A strong relationship
was also reported between the number of highly deformable
plaques on palpography and both the clinical presentation
(stable angina pectoris vs. ACS) of patients and circulating
C-reactive protein levels (57,58). In vivo studies have
confirmed the good correlation between strain values and
histopathology (55), fatty plaques being identified with a
Technical Characteristics of Invasive Techniques and Assumption ThaTable 2 Technical Characteristics of Invasive Techniques and Ass
Physical Property Technique Assumption Energy, MHz
Acoustic Conventional
IVUS
The backscattered
signal is different
among lipid pool,
fibrous, and calcified
tissues
Ultrasound
30–40
IVUS-RF
analysis
RF data are supposed
to be more directly
related to the
interaction of
ultrasound with the
tissue
Ultrasound
30–40
Palpography Measures the local rate
of strain in response
to the pulsating
force of blood
pressure. Fibrous
and calcified
plaques are stiffer
than lipid-rich
plaques
Ultrasound
20–30
Magnetic IV-MRI Calculates the water
diffusion coefficient,
which is less in lipid-
rich than in fibrous
plaques
NA
Light scattering/
absorbance
Angioscopy Direct visualization of
the endothelial
surface
Light
OCT Uses low-coherence
interferometry to
generate ultra-high-
resolution images
Near-infrared
light
NIRS Different molecules
absorb and scatter
near-infrared light
differently allowing
for the chemical
characterization of
biological tissues
Near-infrared
light
Heat production Thermography Plaque inflammation
and neoangiogenesis
produce heat
measured at the
surface of the
plaque
NA
RF  radiofrequency; other abbreviations as in Table 1.sensitivity and specificity of 100% and 80%, respectively. sThus, these studies suggest that palpography holds con-
siderable promise for the identification of vulnerable
plaques.
Optical coherence tomography. OCT was developed for
cross-sectional imaging in biological systems. OCT uses
low-coherence interferometry to generate a 2-dimensional
image of optical scattering with ultra-high resolution (4 to
20 m), which constitutes a definite advantage for vulner-
ble plaque imaging (59–62). Because OCT uses light to
reate the image, it has limited tissue penetration (2 to 3
m) and is attenuated by blood, thus requiring the use of
aline flushes, occlusion balloons, or other techniques to
btain good-quality images (63). In ex vivo experiments,
CT has been shown to identify plaque morphology with a
itimates Their Use in Vulnerable Plaque Assessmenttion That Legitimates Their Use in Vulnerable Plaque Assessment
elength, m
Frame Rate
(Frames/s) Penetration
Thermal
Resolution°
Spatial
Resolution, m
35–80 7–30 8–10 mm NA 150
35–80 7–30 8–10 NA 100–200
35–80 10 NA NA 200–400
NA NA 250 NA 120
0.4–0.8 NA NA 200
1.3 15–20 2–3 mm NA 4–20
0.8–2.5 NA 1–2 mm NA NA
NA NA NA 0.02°C 500t Legump
Wavensitivity between 71% and 96% and a specificity between
1966 Vancraeynest et al. JACC Vol. 57, No. 20, 2011
Imaging the Vulnerable Plaque May 17, 2011:1961–7990% and 98% (64). In patients undergoing percutaneous
intervention, OCT has also been shown to favorably com-
pare with IVUS for plaque characterization (65). Interest-
ingly, thanks to its high-resolution capabilities, OCT allows
for the recognition of the features associated with TCFA
(cap thickness 65 m) and is more accurate than IVUS
and angioscopy to identify plaque ruptures, plaque erosions,
and thrombi (44,66–69). Moreover, it is important to
specify that OCT is the only technique able to detect
eroded plaques, thanks to its high spatial resolution. In
preliminary studies, OCT was also shown to permit
quantification of macrophage content in the fibrous cap
(Fig. 5) (70,71). Finally, OCT-elastography, OCT-
Figure 2 Representative IVUS Image of Vulnerable Atheroscler
(Left) The right coronary angiogram showing luminal irregularities. (A) Mild concen
with high echogenic density. (Right) Coronary occlusion occurring 3 months after
plaque with echolucent area had been seen by intravascular ultrasound (B). Modi
Figure 3 Four Cross-Sectional Images From Proximal to Distal
Gray-scale intravascular ultrasound (IVUS) is displayed on the upper panels, and r
fibrous cap overlying a necrotic core can be seen in A. In B, another thick fibroath
core. In D, a thin-cap fibroatheroma can be seen. (C) Minimal lumen diameter site
and white, respectively. Reprinted, with permission, from Surmely et al. (43). MLDDoppler, and polarization-sensitive OCT offer further pos-
sibilities to assess plaque characteristics (72).
Near-infrared spectroscopy. Near-infrared spectroscopy
(NIRS) is based on the absorbance of light by organic
molecules. Because different molecules absorb and scatter
near-infrared light differently (73), NIRS allows for the
chemical characterization of biological tissues and can be
used to assess lipid and protein content in atherosclerotic
plaques (74). The probability of high lipid content at the
interrogation site is displayed on a color scale and is termed
a “chemogram” (Fig. 6). With this method, lipid-rich cores
can be detected with an area under the curve of 0.86 (75). In
explanted specimens of human aorta, NIRS identifies the
laque
sion. (B) Eccentric lesion with an echolucent area (arrow). (C) Eccentric lesion
inclusion. The coronary is occluded at the portion (arrow) where the eccentric
ith permission, from Yamagishi et al. (27).
in the Same Patient Coronary Lesion Obtained by IVUS and VH
ructed IVUS-virtual histology images are displayed on the lower panels. A thick
can be seen, but the thick overlying fibrous cap contains small spots of necrotic
us, fibro-fatty, necrotic core, and dense calcium are labeled green, yellow, red,
nimal lumen diameter.otic P
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May 17, 2011:1961–79 Imaging the Vulnerable Plaquehistological hallmarks of plaque vulnerability, such as a lipid
pool, a thin cap, and inflammatory cells with a sensitivity
between 77% and 90% and a specificity between 89% and
93% (76). Preliminary data have shown that reliable infor-
mation can be obtained in vivo as well (77), despite blood
flow and cardiac motion. Further studies are nonetheless
needed to establish the accuracy and reproducibility of the
method in daily clinical practice.
Intravascular magnetic resonance. Pulsed field gradient
magnetic resonance imaging (MRI) has recently been used
to calculate the water diffusion coefficient in atherosclerotic
plaques (78). Because water diffusion is less in lipid-rich
than in fibrous plaques, this approach offers the opportunity
to assess and quantify lipid content in atherosclerotic vessels,
such as the aorta or the coronary arteries (79). The regional
lipid content is color-coded and displayed over a conven-
tional gray-scale image with a spatial resolution of 100 m.
n preliminary ex vivo studies, correlation between MRI and
istology was good, with a sensitivity of 100% and a
pecificity of 89%. The needs to stabilize the catheter by use
f an occluding balloon and to mechanically rotate the
atheter are the main limitations of this new method. Yet,
reliminary data obtained in vivo, in human iliac arteries,
ndicate that intravascular MRI might be superior to IVUS
n identifying the lipid, fibrous, and calcified components of
Figure 4 Post-Mortem Vulnerable Coronary Plaque
Post-mortem vulnerable coronary plaque marked (arrow) in intravascular ultrasoun
togram, a vulnerable plaque is indicated by a high strain on the surface. In the co
and a lipid pool (LP). Reprinted, with permission, from Schaar et al. (56).he plaques (80,81). bngioscopy. Angioscopy permits direct visualization of the
urface of the plaque and the detection of thrombi. In
oronary angioscopic images, plaque color is evaluated and
raded as white, light yellow, yellow, or intense yellow (82).
tudies have shown that yellow plaques usually contain
ore lipids, exhibit more positive remodeling thin fibrous
aps (Fig. 7), and are more often associated with intralumi-
al thrombi (82–84). Furthermore, the number of yellow
laques is a strong predictor of subsequent ACS (85–87).
hanges in plaque color have also been used to evaluate the
fficiency of therapeutic interventions, such as statins (88).
he main disadvantages are the need for blood displace-
ent (as for OCT), the subjectivity of the assessment, and
he inaccessibility of small vessels. Although angioscopy has
een used for several decades, it remains a research tool, and
ts factual accuracy/patient is poor.
hermography. Thermography is based on the assump-
ion that plaque inflammation and neoangiogenesis produce
eat that can be measured at the surface of the plaque with
dedicated catheter (89). Because vulnerable plaques are
ore cellular and inflammatory than stable plaques, they
ould be detected with this technique. Ex vivo experiments
n carotid samples have shown that plaque temperature
orrelated positively with cell density and macrophage
ontent and inversely with plaque thickness and the distance
elastogram (B), macrophage staining (C), and collagen staining (D). In the elas-
nding histology, a high amount of macrophages (C) is visible with a thin cap (D)d (A),
rrespoetween the cell clusters and the luminal surface (90–92).
1968 Vancraeynest et al. JACC Vol. 57, No. 20, 2011
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mans with ACS, the temperature difference between
plaques and healthy vessel walls reaching as much as 1.5°C
(93) and correlating with the morphological features asso-
ciated with plaque vulnerability such as positive remodeling
(94,95). The major limitation of the method relates to the
blood flow “cooling effect” (89), which might require sys-
tematic interruption of blood flow to achieve consistent and
reproducible results (96).
Ultrasound-derived shear stress imaging. Although lo-
calized low shear stresses have been associated with
plaque formation (97), localized high shear stresses have
been linked with an increased risk of plaque rupture (Fig. 8)
(98). Three-dimensional IVUS assessment of local shear
stress has recently been shown to be feasible and might
prove to be a useful approach to identify vulnerable
plaques and potential sites of upcoming rupture. Larger
studies are needed.
Noninvasive Assessment of Plaque Vulnerability
Noninvasive assessment of plaque vulnerability targets a
different patient population than intravascular imaging (i.e.,
asymptomatic individuals who have not yet presented with
Figure 5 OCT Images of Human Atherosclerotic Arterial Segme
Raw (A) and logarithm base 10 (B) optical coherence tomography (OCT) images o
sponding histology for A and B (CD68; original magnification 100). Raw (D) and
phages within the fibrous cap. (F) Corresponding histology for D and E (CD68; origan acute vascular event but are at high risk to develop one).At the present stage of development, these imaging modal-
ities are not well-suited for imaging of the coronary arteries,
owing mainly to the small size and continuous movement of
these imaging targets. By contrast, they can be and have
already been used successfully for carotid imaging.
Table 3 provides the histological targets, validation,
potential applicability for coronary arteries, and limitations
of each technique.
Multidetector computed tomography. Over the past 10
years, technical improvements—including faster gantry ro-
tation, increased number of detectors, decreased slice thick-
ness, and use of dual x-ray sources—have considerably
increased the temporal and the spatial resolution of multi-
detector computed tomography (MDCT) (99). Accord-
ingly, in recent series, the diagnostic accuracy of 64-detector
MDCT to identify significant coronary artery disease has
reached more than 95%.
By virtue of its ability to measure local tissue attenuation,
MDCT also allows imaging of the vessel wall, potentially
providing insights into the characteristics and extent of
intramural atherosclerosis (100,101). MDCT can also help
detect some of the features associated with plaque vulnera-
bility, such as more positive remodeling, the presence of
btained at Autopsy
roatheroma with a low density of macrophages within the fibrous cap. (C) Corre-
hm base 10 (E) OCT images of a fibroatheroma with a high density of macro-
agnification 100). Reprinted, with permission, from Tearney et al. (70).nts O
f a fib
logarit
inal mspotty calcifications, and a lower plaque density (30
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May 17, 2011:1961–79 Imaging the Vulnerable PlaqueHounsfield units) (102–105). In patients with ACS, the
combined presence of these 3 features allows identification
of the unstable lesion with a positive predictive value, a
negative predictive value, and an accuracy of 95%, 60%, and
70%, respectively (104). The MDCT criteria for plaque
vulnerability have been validated against VH, in ACS
patients (106), and against histopathology, in patients un-
dergoing carotid endarterectomy (107,108). Whenever
identified in patients with atherosclerotic risk factors, these
features have been shown to predict the occurrence of
subsequent ACS (hazard ratio: 22.8) (Fig. 9) (109). Undoubt-
edly, MDCT is currently the first-line method in the search
for vulnerable plaque.
By use of newly designed, iodine-based contrast agents
that selectively accumulate into macrophages, MDCT also
offers the opportunity to selectively detect plaques contain-
ing macrophages (i.e., vulnerable plaques). In a rabbit model
of atherosclerosis, Hyafil et al. (110,111) demonstrated that
the signal obtained with MDCT correlated well with
histopathology as well as with glucose uptake as measured
by positron emission tomography (PET) (Fig. 10). Al-
though promising, these results need to be confirmed in
patients with atherosclerotic risk factors. Risk-benefit stud-
Figure 6 Scanning NIRS Performed Through Blood in a Coronar
(A) Chemogram image indicating artery wall lipid content (x axis  pullback in mil
and yellow for high probability of lipid core plaque of interest (LCP). The lipid core
scale. (B) Summary (block chemogram) of LCP presence at 2-mm intervals in 4 pr
 small or thick-capped fibroatheroma; dark orange  intimal xanthoma and path
tions along the artery (dotted lines). Black bars denote 1 mm. Image interpretatio
The block chemogram shows that the strongest LCP signals extend 5 to 11 mm. T
absence of LCP. Reprinted, with permission, from Gardner et al. (75).ies will also be needed before MDCT can be used for thedetection and longitudinal assessment of vulnerable plaques
in patients, because repeated radiation exposure remains an
important and worrying limitation of x-ray imaging modal-
ities (112).
Magnetic resonance imaging. MRI evaluates the biophys-
ical response of tissues placed in a strong static magnetic
field that are transiently exposed to electromagnetic RF
pulses (113). By using different contrast weightings—such
as T1-weighted, T2-weighted, proton-density-weighted,
and time-of-flight scanning—MRI can provide insights
into the biological characteristics of the tissue of interest,
such as its water, lipid, and fibrous content. Accordingly, it
has been increasingly used to characterize atherosclerotic
plaques. Magnetic resonance imaging is best suited for the
study of large or “static” arteries, such as the carotid arteries.
Because of their small dimensions and their continuous
motion during data acquisition, coronary arteries remain
more difficult to image. This is the main reason why most of
the data on the detection of vulnerable plaques with MRI
have been obtained in large arteries.
Lipid and fibrotic plaque components have been accurately
quantified on T2-weighted images, in both experimental
animals (114) and humans (115,116). T2-weighted images
ment From an Autopsy Heart
s; y axis  rotation in degrees). Each pixel is marked with red for low probability
n index (top right) indicates amount of lipid in scanned artery on a 0-to-1,000
ity categories. (C) Map of histological classifications (yellow  LCP; light orange
intimal thickening; red  all other types). (D) Movat cross-sections from loca-
chemogram shows prominent lipid core signal at 2 to 16 mm, occupying 180°.
ar- infrared spectroscopy (NIRS) signals at 18 and 42 mm correctly indicatey Seg
limeter
burde
obabil
ologic
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he nehave also been used to measure the fibrous cap thickness (117)
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hemorrhages (119), 2 features that are commonly found in
symptomatic carotid atherosclerosis (120). A good agreement
between MRI and histopathology (kappa  0.69) was found
or the identification of lipid-rich necrotic cores and intra-
laque hemorrhages in human carotid plaques (115). The main
imitation of MRI in identifying vulnerable plaques is its
elatively poor reproducibility (121,122). Alternative imaging
strategies have been recently developed to overcome this
limitation. These include diffusion-weighted imaging, which
pictures the various water diffusion coefficients in the plaque
(123), and gadofluorine-enhanced imaging, which can be used
either as a blood pool agent to detect plaque neovascularization
and inflammation (Fig. 11) (124,125) or as an extracellular
matrix agent to enhance detection of lipid-rich plaques (126).
Magnetic resonance imaging also allows for targeted
molecular imaging, which holds considerable promise for
the specific characterization of the different plaque com-
ponents. For instance, plaque inflammation can be tar-
geted with ultrasmall superparamagnetic particles of iron
oxide, which accumulate in plaque macrophages (127–129);
plaque neoangiogenesis can be imaged with alpha(v)beta(3)-
integrin-targeted paramagnetic nanoparticles or a mimetic of
arginine-glycine-aspartic acid (RGD) peptide grafted to
gadolinium-diethylenetriamine penta-acetic acid (130,131);
VCAM-1–expressing endothelial and inflammatory cells
Figure 7 Angioscopic and Corresponding OCT Images Obtained
In the angioscopic images, plaque color is graded as white (A-1), light yellow (B-
images, a lipid pool (*) is characterized by a signal-poor region (A-2, B-2, C-2, D-2
lumen and inner border of lipid pool in the OCT image, and its thickness is measu
Kubo et al. (87).can be detected with a dedicated agent (132); and oxidation-rich lesions can be assessed with antibodies that recognize
oxidation-specific epitopes (133).
Thanks to its submillimeter resolution, MRI is thus a
promising method for the simultaneous assessment of
plaque morphology and composition. Nevertheless, further
technical improvements are needed before it can be used to
study smaller vessels such as coronary arteries. The clinical
value of MRI in predicting acute vascular events also
remains to be determined.
Nuclear imaging. Nuclear imaging modalities, such as
SPECT and positron emission tomography (PET), are
intrinsically designed to image systemic disorders such as
atherosclerosis. Thanks to their whole-body and targeted-
imaging capabilities, SPECT and PET offer the opportu-
nity to specifically identify the various components of
atherosclerotic plaques along the entire length of the arterial
tree. Single-photon emission computed tomography and
PET differ in several ways. Because of its better spatial
resolution (4 to 5 mm vs. 1 to 1.6 cm) (134,135) and its
intrinsic capability to quantify biological processes in abso-
lute terms, PET has been used in most of the studies on
nuclear imaging of atherosclerosis.
18F-labeled fluorodeoxyglucose (FDG) is currently the
most validated tracer for imaging of plaque inflammation.
In metabolically active cells such as activated macrophages,
FDG competes with glucose for facilitated transport sites
and phosphorylation by hexokinase to yield FDG-6–
atients Presenting With Acute Coronary Syndromes
low (C-1), or intensive yellow (D-1). In the optical coherence tomography (OCT)
fibrous cap is identified as a signal-rich region between the coronary artery
the thinnest part (A-3, B-3, C-3, D-3; arrows). Reprinted, with permission, fromin P
1), yel
). The
red atphosphate. Because FDG-6–phosphate has low membrane
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glycolytic or the glycogen synthetic pathways, it progres-
sively accumulates in cells as the end product of the
phosphorylation reaction. The intracellular accumulation of
FDG-6–phosphate can then be imaged and quantified with
PET. In animals with experimental atherosclerosis (136)
and humans with carotid atherosclerosis (135,137), areas of
high FDG uptake have been shown to co-localize with areas
of macrophages accumulation, irrespective of plaque size
(135) or luminal narrowing (137). The presence of high
FDG uptake has also been shown to correlate with circu-
lating markers of inflammation such as matrix metallopro-
teinases (138,139). In cancer patients undergoing FDG
PET imaging for staging of their neoplastic disease, in-
creased FDG uptake in large arteries was recently shown to
predict subsequent acute ischemic events (140). Finally, the
FDG PET signal has been shown to be highly reproducible
(141,142) and to vary in amplitude with therapeutic interven-
tions, thus suggesting a possible role in treatment monitoring
(143,144). Although FDG imaging of large-artery inflamma-
tion holds considerable promise for the early identification of
vulnerable plaques, imaging of the coronary arteries has been
more challenging, owing mainly to the intense tracer uptake in
adjacent myocardium (134,145). Adequate visualization of
Figure 8 Representative Color Mapping of the Shear Stress D
of a 60-Year-Old Patient Presenting With Unstable A
The longitudinal intravascular ultrasound image. Plaque rupture was observed at t
A localized elevation of shear stress was observed on the plaque surface (red circ
ing coronary artery. Reprinted, with permission, from Fukumoto et al. (98).coronary plaque inflammation with FDG PET will probablyrequire suppression of the myocardial FDG signal, for instance
by use of low-carbohydrate, high-fat diets (Fig. 12) (146,147).
Besides glucose uptake, numerous other metabolic and
signaling pathways associated with plaque vulnerability have
been targeted with nuclear imaging modalities. These include
the oxidation and accumulation of LDL with 125iodine-labeled
xidation-specific antibodies (148), matrix metalloproteinase
ctivity with 99mtechnetium-labeled matrix metalloprotease
inhibitors (149), macrophage apoptosis with 99mtechnetium-
abeled annexin-V (150–152), and finally monocyte recruit-
ent with either 99mtechnetium-labeled monocyte chemotac-
ic protein-1 (153) (a key player in the transendothelial
igration of mononuclear cells)—an 18F-labeled peptide,
hich can be internalized by endothelial cells through
CAM-1–mediated binding (154)—or the alpha(v)beta(3)-
ntegrin-targeted PET tracer, 18F-galacto-RGD (Fig. 13)
(155).
Although nuclear imaging is currently the leading modality
for the detection of vulnerable atherosclerotic plaques, repeated
radiation exposure will probably limit its widespread use for the
longitudinal monitoring of patients with atherosclerotic risk
factors, many of whom are women of childbearing age. Thus,
future studies should probably concentrate not only on dem-
onstrating the diagnostic accuracy of these techniques but also
bution in the LAD
a
ximal site of the plaque (*) (A). Color mapping of the shear stress distribution.
). This portion corresponded to the rupture site (*). LAD  left anterior descend-istri
ngin
he pro
le) (Bon investigating their risk/benefit ratio.
p
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Imaging the Vulnerable Plaque May 17, 2011:1961–79Ultrasound imaging. Ultrasound contrast agents have
aved the way for plaque characterization with ultrasound.
ltrasound contrast agents consist of acoustically active
icrobubbles with a diameter of 3 to 4 m. When exposed
to an ultrasound field, these microbubbles expand and
contract rhythmically, producing strong backscattered sig-
nals that can be detected by conventional ultrasound sys-
tems. Furthermore, microbubbles also produce a specific
Noninvasive Technique for Imaging the Vulnerable PlaqueTable 3 Noninvasive Technique for Imaging the Vulnerable Plaq
Histological or Physiological Targets
Histological
Correlation
Coefficient
MDCT Eccentric pattern, outward remodeling, spotty
calcifications
NA
Plaque composition derived from HU 0.73 (109)
Cap thickness 0.88 (108)
Macrophages (N1177-specific contrast agent) 0.63 (112)
MRI Plaque composition, lipid-rich necrotic core,
intraplaque hemorrhage
0.93 (127)
Cap thickness 0.73 (118)
Neoangiogenesis Gadofluorine-M or
gadolinium
0.67 (125)
0.80 (126)
V3-integrin-targeted
paramagnetic
nanoparticles
NA
Macrophages Iron oxide nanoparticle p  0.001 (128)
Micelles containing
gadolinium and
antibodies binding
oxidation-specific
epitopes
NA
VCAM-1 (endothelial
cells and macrophages)
0.93 (133)
PET Macrophage-
inflammation
(FDG) 0.81 (137)
0.85 (138)
18F-labeled VCAM-1
affinity ligand
0.79 (155)
Neoangiogenesis-inflammation
(18F-galacto-RGD targeting V3-integrin)
p  0.003 (156)
SPECT Macrophages–
inflammation
Oxidized LDL (125iodine-
labeled oxidation
specific antibodies)
0.93 (149)
Macrophage apoptosis
(99mTc-labeled
annexin-V)
0.47 (151)
Metalloproteinases
activity (99mTc- MMP
inhibitors)
0.64 (150)
Monocyte recruitment
(99mTc- MCP-1)
0.87 (154)
Contrast-
ultrasound
imaging
Neoangiogenesis 0.68 (158)
See text for details.
FDG  18F-labeled fluorodeoxyglucose; HU  Hounsfield unit; LDL  low-density lipoprotein;
etalloprotease; PET  positron emission tomography; SPECT  single-photon emission comp
CAM  vascular cell adhesion molecule; other abbreviations as in Table 1.nonlinear signal that helps differentiate them from sur-rounding tissues (25,156). Because ultrasound contrast
agents are pure intravascular tracers, contrast-enhanced
ultrasonography allows for the assessment of the amount of
blood contained in the microvasculature within the region
of interest. This principle has been exploited to semi-
quantitatively assess neovascularization in carotid plaques.
Significant acoustic plaque enhancement has been corre-
lated with both histopathology (CD31 staining) (157,158)
tion (Ref. #)
Prediction of
Clinical Outcomes
(Ref. #)
Already Applied
for Coronary
Arteries LimitationsAccuracy
NA HR: 22.8 (110)  Radiation,
contrast agent,
overlap in the
attenuation
spectrum of
lipid and
fibrous plaque
0%, Acc: 73%
)

NA NA 
NA NA 
8%–92%,
6%–98%,
87% (116)
NA  Cardiac motion
artefact,
contrast agent,
limited spatial
resolution
NA NA 
NA NA 
NA NA 
1%, Sp: 89%,
92% (128)
NA 
NA NA 
NA NA 
NA HR: 14.1 (142)  Myocardial
uptake of FDG,
radiation,
cardiac motion
artefact,
limited spatial
resolution
NA NA 
NA NA 
NA NA  Radiation, cardiac
motion
artefact,
spatial
resolution
NA NA 
NA NA 
NA NA 
NA NA  Limited spatial
resolution,
penetration
monocyte chemotactic protein; MDCT  multidetector computed tomography; MMP  matrix
mography; Tc  technetium; USPIOs  ultrasmall superparamagnetic particles of iron oxide;ue
Valida
Sp: 9
(108
Se: 7
Sp: 8
Acc:
Se: 9
Acc:
MCP 
uted toand clinical presentation (159).
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molecular imaging, with specific ligands, such as mono-
clonal antibodies, which are attached onto the shell of the
microbubble. Because microbubbles are constrained to
the intravascular space, only molecular targets appearing
on the endothelial surface can be imaged. When the
targeted microbubbles stream through the capillary net-
Figure 9 CT Angiography Obtained Before and Invasive Corona
(A) Curved multiplanar reformation images of left anterior descending (LAD), left c
tion plaque, and spotty calcification were detected in LAD #6 on coronary compute
months after CT angiography, and LAD #6 was determined as the culprit lesion on
Reprinted, with permission, from Motoyama et al. (109).
Figure 10 N1177-Enhanced CT and Corresponding FDG PET of
(A) Fused positron emission tomography (PET)/computed tomography (CT) corona
and corresponding axial aortic sections acquired before (B and D) and at 2 h afte
(C and E). In the same rabbit, aortic regions with high (A; red cross) and low (A;
with strong (E; red cross) and weak (C; white cross) intensities of enhancement
tively. Reprinted, with permission, from Hyafil et al. (111).work, they are retained locally by the specific interaction
between the antibody and the antigen of interest. The
presence and extent of retention can then be assessed with
ultrasound imaging, usually after subtraction of the signal
emanating from the circulating microbubbles. This emerging
application of contrast-enhanced ultrasonography has been
successfully tested in animal models of atherosclerosis by
giogram Obtained After ACS in Patient
ex (LCX), and right coronary artery (RCA). (B) Positive remodeling, low-attenua-
ography (CT) angiography. (C) Acute coronary syndromes (ACS) occurred 6
asis of invasive coronary angiogram findings. LCA  left coronary artery.
From Atherosclerotic Rabbit
of aorta obtained at 3 h after injection of 18F-labeled fluorodeoxyglucose (FDG)
tion of N1177, an iodine-based contrast agent that accumulates in macrophages
cross) activities identified with PET at 3 h after injection of FDG were associated
ed with CT at 2 h after injection of N1177 on corresponding axial views, respec-ry An
ircumfl
d tom
the bAorta
l view
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Imaging the Vulnerable Plaque May 17, 2011:1961–79targeting VCAM-1 and P-selectin in aortic plaques (Fig. 14)
(160–162). Up to now, molecular ultrasound imaging has
remained in the domain of preclinical research.
Future Perspectives and Concluding Remarks
The detection of plaque vulnerability in vivo is becoming
a reality, thanks to the various techniques described in
this review. Currently, however, there is little evidence
that the presence of vulnerable plaques is associated with
an increased risk of subsequent acute ischemic events
(27,48,86,109,140). Therefore, before these methods can
Figure 11 Transverse T1-Weighted MR Images of Atherosclero
(A) Pre-contrast imaging; (B) 24 h after gadofluorine-M injection, a contrast agent
lar structures such as neovessel. (C) Corresponding histopathologic section is sta
ids (3 to 9 o’clock positions), matching the plaque enhancement seen with gadofl
necrotic core. Reprinted, with permission, from Sirol et al. (124).
Figure 12 Representative Images of Coronary Tree FDG Uptake
Representative images of coronary tree FDG uptake (arrows). FDG PET (A), CT (B
suppression with a low-carbohydrate, high-fat preparation. Abbreviations as in Figube implemented into daily clinical routine, their diagnos-
tic and predictive accuracy need to be evaluated in large
groups of patients, in multicenter, randomized, con-
trolled trials. The PROSPECT study brought us impor-
tant information, and other studies are still underway
(163).
We also need to learn which of the different morphological
(thin fibrous cap, macrophage content, neoangiogenesis, and
the like), molecular (e.g., matrix metalloprotease-activity,
caspase-activity), biological (temperature, glucose metabolism),
or mechanical features of vulnerable plaques are clinically
relevant to the outcome of patients. It is likely that more than
bbit Abdominal Aorta at 2 Different Time Points
ehaves in vivo as a blood pool agent and tends to persist longer in small vascu-
ith combined Masson elastin trichrome. The atherosclerotic plaque is rich in lip-
-M. Magnification 4. Ad  adventitia; FC  fibrous cap; L  lumen; NC 
h Corresponding Angiographic Images
CT (C), and coronary angiography (D) from patient with good myocardial uptake
Reprinted, with permission, from Wykrzykowska et al. (147).tic Ra
that b
ined w
uorineWit
), PET/
re 10.
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assessment. In this regard, combined imaging will be necessary.
Studies will also be needed to determine how the infor-
mation provided by plaque imaging can be used. For
instance, if the goal of imaging is to more precisely risk-
stratify patients with atherosclerotic risk factors, its predic-
tive accuracy must be better than that of the prevailing risk
assessment methods, such as the Framingham Risk Score,
C-reactive protein levels, or the coronary calcium score
(164). Today, no data are available to indicate this is indeed
the case. The target population should also be better-
defined. It is indeed likely that the information gained from
imaging will only surpass that of the currently available tools
in low-risk or intermediate-risk populations. But in such
categories, the “number needed to screen” by imaging will
have to be more important. Therefore, plaque imaging must
be not only accurate but also widely available and affordable.
Alternatively, if the goal of imaging is to detect rupture-
prone plaques before they cause an acute ischemic event,
imaging must have a high positive predictive accuracy—
particularly at the coronary level—so that individual
rupture-prone lesions can be timely treated. For this pur-
Figure 13 Vascular Inflammation Imaging by Studying the Upta
Into Atherosclerotic Lesions of Hypercholesterolemic
In vivo 18F-galacto–arginine-glycine-aspartic acid (RGD)-PET imaging showed focal incre
aortic arch and aortic root as seen in contrast-enhanced CT angiography (arrow in C).
Figure 14 Images From the Aortic Arch of Atherosclerotic Mic
Images from the aortic arch of atherosclerotic mice with high-frequency (40 MHz) u
aorta at baseline with the aorta defined by dashed lines before contrast administr
background-subtraction and color-coding (color scale at bottom; C). Reprinted, wipose, data on the natural history of these rupture-prone
lesions, including their persistence or their spontaneous
healing capabilities, will also be needed (165,166). While
awaiting the results of the SECRITT I (Santorini Criteria
for Investigating and Treating Thin Capped Fibroathe-
roma) trial, which should answer some of these questions,
one must recognize we are still far from the mark (167,168).
If the treatment of vulnerable plaque modifies favorably the
outcome of patients, it is likely that vulnerable plaque
imaging will not be an elusive goal.
Finally, the question of how often testing must re-
peated needs to be addressed. If repeated imaging is
mandatory, safety will certainly become a major issue,
because most of the currently available methods use
ionizing radiation, require contrast injections, or need a
vascular access.
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arrow in A and B) in the signal intensity colocalizing with calcified atherosclerotic
viations as in Figure 10. Reprinted, with permission, from Laitinen et al. (155).
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